Holen Sie sich die Stockscreener-App
65.41
12.14%
-9.04
Handel nachbörslich:
65.51
0.10
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$74.45
Offen:
$66.06
24-Stunden-Volumen:
6.91M
Relative Volume:
3.94
Marktkapitalisierung:
$31.88B
Einnahmen:
$10.40B
Nettoeinkommen (Verlust:
$980.00M
KGV:
33.12
EPS:
1.9749
Netto-Cashflow:
$1.61B
1W Leistung:
-10.16%
1M Leistung:
-12.35%
6M Leistung:
-11.93%
1J Leistung:
-31.86%
1-Tages-Spanne:
$64.75
$67.66
1-Wochen-Bereich:
$64.75
$75.42
52-Wochen-Spanne:
$64.75
$97.14
Alcon Inc Stock (ALC) Company Profile
Compare ALC vs ISRG, BDX, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
65.41 | 36.29B | 10.40B | 980.00M | 1.61B | 1.9749 |
ISRG
Intuitive Surgical Inc
|
451.73 | 159.86B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.76 | 41.01B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
42.01 | 38.32B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
209.64 | 30.15B | 5.54B | 1.52B | 1.74B | 10.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-09 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-11 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
BTIG lowers Alcon stock price target to $82 on lower valuation - Investing.com UK
Alcon stock slides as Q1 sales miss expectations and reported profitability drops sharply - Quiver Quantitative
Alcon Kicks Off 2026 on Solid Results as New Innovations Pay Dividends - Morningstar
Alcon declines 10% after Q1 revenue misses consensus - Seeking Alpha
Alcon Q1 2026 Earnings Call Transcript - Benzinga
Alcon Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Swiss eye care firm Alcon’s quarterly revenue rises less than expected - WHTC
Alcon slides after revenue misses forecasts, operating profit falls sharply By Investing.com - Investing.com Canada
Alcon slides after revenue misses forecasts, operating profit falls sharply - Investing.com
Alcon shares see BofA reiterate underperform on soft Q1 results By Investing.com - Investing.com Nigeria
Alcon shares see BofA reiterate underperform on soft Q1 results - Investing.com
Alcon Price Target Declines as AlphaValue/Baader Cuts Estimates on Rising Competition, Expenses - marketscreener.com
Earnings Preview: Alcon to Report Financial Results Pre-market on May 06 - Moomoo
Alcon Logs Lower Q1 Net Income; Net Sales, Other Revenue Rise - marketscreener.com
Alcon : Earnings Document (Q1 2026 Interim Financial Report) - marketscreener.com
Alcon Inc. (ALC) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Alcon Q1 2026 Sales Rise 10% as New Eye-Care Products Power Growth and $1.5 Billion Buyback - TipRanks
Earnings Flash (ALC) Alcon Posts Q1 Revenue $2.69B, vs. FactSet Est of $2.7B - marketscreener.com
Alcon Q1 Core Earnings, Revenue Rise; 2026 EPS Outlook Revised - marketscreener.com
Alcon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Press Release: New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum From Unity and Tryptyr Builds - Moomoo
Alcon earnings on deck: Can new products drive double-digit growth? - Investing.com Canada
Earnings Snapshot: Alcon plans to offset FY ~$100M tariff impact, guides profit above consensus - MSN
MSN Money - MSN
ALC Stock Price, Quote & Chart | ALCON INC (NYSE:ALC) - ChartMill
Assessing Alcon (SWX:ALC) Valuation After Recent Share Price Weakness - Yahoo Finance
Alcon Board Change And Vision Research Progress Shape Investor Expectations - Yahoo Finance
US Startup PerZeption Inc. Announces Collaboration with Alcon Research - Yahoo Finance
Alcon Announces Results of 2026 Annual General Meeting - BioSpace
Alcon shareholders approve CHF 0.28 dividend, add Scott Herren - Stock Titan
Alcon Inc. Elects R. Scott Herren as New Independent Member of the Board - marketscreener.com
BofA Securities Maintains Alcon(ALC.US) With Sell Rating, Cuts Target Price to $69.54 - Moomoo
How Alcon Inc. (ALC) Affects Rotational Strategy Timing - Stock Traders Daily
Alcon Stock Rises Following the FDA Approval of TRYPTYR - MSN
Is Alcon Inc (ALC) a Bargain After 3.4% Drop? GF Value Says Unde - GuruFocus
Lensar stock slumps after hours on ending merger deal with Alcon over FTC pushback - MSN
World Council of Optometry and Alcon Video Series Summarizes TFOS DEWS III - InvisionMag.com
Alcon Inc. stock (CH0432492467): Is its eye care dominance strong enough to unlock new upside? - AD HOC NEWS
STAAR Surgical falls as proxy adviser recommends against revised Alcon deal (update) - MSN
STAAR Surgical stock jumps 10% after Alcon sweetens buyout offer — investor says deal is 'worth substantially more' - MSN
STAAR Surgical vote on Alcon may be delayed againReport - MSN
Alcon Inc. (ALC) Stock Analysis: 24.91% Potential Upside Makes This Healthcare Giant Worth Watching - DirectorsTalk Interviews
STAAR Surgical jumps after Alcon raises offer to $30.75/share in cash (update) - MSN
STAAR Surgical sinks as it plans to terminate sale to Alcon (update) - MSN
STAAR Surgical's largest holder to vote against Alcon bid - MSN
Alcon slips as Q4 financial results miss on both lines - MSN
Sight Sciences awarded $55.4 million in patent case against Alcon By Investing.com - Investing.com Canada
Sight Sciences awarded $55.4 million in patent case against Alcon - Investing.com
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.85%
7.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):